A Whale Takes Profits of $27 Million on BTC Short Position, Plans to Short at Larger Scale Again
BlockBeats News, May 19th, according to Hyperinsight monitoring, a major short position on Hyperliquid significantly closed for profit, simultaneously unwinding BTC and ETH short positions: The BTC short position was closed for approximately 363.2 coins (valued at around $27.8 million) at a closing price of $76,774; the ETH short position was closed for 2808 coins (valued at around $5.98 million) at a closing price of $2,130, with a total closing size of approximately $33.8 million.
After the closure, the address promptly placed a new sell order, planning to short 257.2 BTC (approximately $40 million) in the $77,500 to $78,000 range, and short 4,484 ETH at $2,230 (approximately $10 million).
Address: 0x32008fcb6bbd16532afc83ca8b6c920dde22c407
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BNP Paribas gives Microsoft (MSFT.US) a "Buy" rating: Azure price increases will be gradually implemented after contract renewals, and a deal with SpaceX may be announced soon.
BNP Paribas has rated Microsoft as "Buy" with a target price of $549.
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.
